- Home
- / Rani Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Rani Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.3
2024-10-29
Market Capitalization
$135.4 M
2024-10-29
Revenue
$1.6 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 2.7M | 1.0M | 1.6M | ||
| General and administrative expense | 27.8M | 26.8M | 26.5M | 23.9M | 19.7M |
| Operating expense total | 63.5M | 50.6M | 39.9M | ||
| EBIT | (51.6M) | (63.5M) | (66.1M) | (53.3M) | (38.3M) |
| EBIT margin, % | -5186.2% | -2346.0% | |||
| Interest income | 89.0K | 1.2M | 3.3M | 1.8M | 827.0K |
| Interest expense | 5.1M | 5.0M | |||
| Pre tax profit | (53.0M) | (63.3M) | (67.9M) | ||
| Income tax expense | 41.0K | 70.0K | |||
| Net Income | (8.3M) | (30.6M) | (67.9M) | (56.6M) | (40.9M) |
| EPS | (1.3) | (1.0) | (1.0) | (0.4) |